...
首页> 外文期刊>American Journal of Pathology >Chromogenic in Situ Hybridization : A Practical Alternative for Fluorescence in Situ Hybridization to Detect HER-2eu Oncogene Amplification in Archival Breast Cancer Samples
【24h】

Chromogenic in Situ Hybridization : A Practical Alternative for Fluorescence in Situ Hybridization to Detect HER-2eu Oncogene Amplification in Archival Breast Cancer Samples

机译:生色原位杂交:荧光原位杂交的实用替代方法,用于检测档案性乳腺癌样品中的HER-2 / neu癌基因扩增

获取原文
获取原文并翻译 | 示例
           

摘要

Determination of HER-2eu oncogene amplification has become necessary for selection of breast cancer patients for trastuzumab (Herceptin) therapy. Fluorescence in situ hybridization (FISH) is currently regarded as a gold standard method for detecting HER-2eu amplification, but it is not very practical for routine histopathological laboratories. We evaluated a new modification of in situ hybridization, the chromogenic in situ hybridization (CISH), which enables detection of HER-2eu gene copies with conventional peroxidase reaction. Archival formalin-fixed paraffin-embedded tumor tissue sections were pretreated (by heating in a microwave oven and using enzyme digestion) and hybridized with a digoxigenin-labeled DNA probe. The probe was detected with anti-digoxigenin fluorescein, anti-fluorescein peroxidase, and diaminobenzidine. Gene copies visualized by CISH could be easily distinguished with a x40 objective in hematoxylin-stained tissue sections. HER-2eu amplification typically appeared as large peroxidase-positive intranuclear gene copy clusters. CISH and FISH (according to Vysis, made from frozen pulverized tumor samples) correlated well in a series of 157 breast cancers (kappa coefficient, 0.81). The few different classifications were mostly because of low-level amplifications by FISH that were negative by CISH and immunohistochemistry with monoclonal antibody CB-11. We conclude that CISH, using conventional bright-field microscopy in evaluation, is a useful alternative for determination of HER-2eu amplification in paraffin-embedded tumor samples, especially for confirming the immunohistochemical staining results.
机译:对于选择曲妥珠单抗(Herceptin) 治疗的乳腺癌患者,确定HER-2 / neu癌基因扩增已成为必需的 。荧光原位杂交(FISH)目前被认为是检测HER-2 / neu扩增的金标准方法,但对于常规组织病理学实验室而言却并不实用。 sup> sup> 我们评估了一种新的原位杂交修饰方法,即显色 原位杂交(CISH),它可以检测HER-2 / neu 基因拷贝与传统的过氧化物酶反应。将档案 福尔马林固定石蜡包埋的肿瘤组织切片 进行预处理(通过在微波炉中加热并使用酶 消化)并与洋地黄毒苷杂交标记的DNA探针。用抗-洋地黄毒苷荧光素,抗-荧光素 过氧化物酶和二氨基联苯胺检测了 探针。在苏木精染色的 组织切片中,使用x40物镜可以轻松区分通过 CISH可视化的基因拷贝。 HER-2 / neu扩增通常以大的过氧化物酶阳性核内基因拷贝簇的形式出现。 CISH和FISH(根据Vysis,由冷冻粉碎的 肿瘤样本)与157种乳腺癌 的相关性很好(kappa系数为0.81)。几种不同的分类 主要是由于FISH的低水平扩增而CISH阴性的 和单克隆抗体 CB-11的免疫组化的结果。我们得出的结论是,使用常规的明场显微镜在评估中,CISH是测定石蜡包埋的肿瘤样品中HER-2 / neu扩增的一种有用的替代方法, > 尤其是用于确认免疫组织化学染色结果。

著录项

  • 来源
    《American Journal of Pathology》 |2000年第5期|1467-1472|共6页
  • 作者单位

    From the Laboratory of Cancer Genetics,Institute of Medical Technology University and University Hospital of Tampere, Tampere, Finland;

    and the Jules Bordet Institute,Brussels, Belgium;

    and the Jules Bordet Institute,Brussels, Belgium;

    and the Jules Bordet Institute,Brussels, Belgium;

    and the Jules Bordet Institute,Brussels, Belgium;

    and the Jules Bordet Institute,Brussels, Belgium;

    From the Laboratory of Cancer Genetics,Institute of Medical Technology University and University Hospital of Tampere, Tampere, Finland;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号